Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Philip Thomas doesn't like to dwell on the disaster that buried him alive - but he can still recall in detail how an unpaid debt saved him.
The deal would set up a free trade zone between the EU and Canada - and could be an important test for the UK's Brexit negotiations.
A mother has won her battle against the Home Office to allow her Nigerian sister into the country - so she can undergo a marrow transplant.